Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Group sequential clinical trials for longitudinal data with analyses using summary statistics.

John M Kittelson1, Katrina Sharples, Scott S Emerson

  • 1Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, 80262, USA. john.kittelson@uchsc.edu

Statistics in Medicine
|June 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events".

Statistics in medicine·2026
Same author

Dispensing of Antiemetics During Pregnancy in Aotearoa New Zealand, 2005-2020.

The Australian & New Zealand journal of obstetrics & gynaecology·2026
Same author

Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.

Lancet (London, England)·2026
Same author

Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials.

Diabetes, obesity & metabolism·2026
Same author

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.

JAMA cardiology·2026
Same author

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

JAMA internal medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
See all related articles

This study introduces methods to accurately analyze longitudinal clinical trial data during interim analyses, preventing biased decisions from non-linear treatment effects. Software is provided to support these robust clinical trial designs.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Longitudinal Data Analysis

Background:

  • Longitudinal endpoints in clinical trials are often analyzed using within-individual summary statistics.
  • Interim analyses with incomplete follow-up data can introduce bias due to non-linear treatment effect trajectories.
  • Existing software lacks comprehensive support for designing and implementing monitoring plans for longitudinal trials.

Purpose of the Study:

  • To develop methods for unbiased interim analyses in longitudinal clinical trials.
  • To provide software for calculating information at interim analyses to guide trial monitoring.
  • To address practical implementation issues, including inconsistent measurement schedules.

Main Methods:

  • Utilizing linear mixed-effects models to account for non-linear time trajectories.

Related Experiment Videos

  • Parameterizing the scientific question by contrasts across fixed measurement times for generalizable inference.
  • Deriving the distribution of treatment effect estimates at interim analyses.
  • Providing Splus/R functions for implementing these methods.

    • Main Results:

    • The distribution of treatment effect estimates at interim analyses is determined.
    • Software is available to calculate interim analysis information, enabling standard group sequential designs.
    • Methods for consistent treatment effect estimation with irregular measurement schedules are presented.

    Conclusions:

    • The proposed methods and software enable robust interim analyses for longitudinal clinical trials, mitigating bias from non-linear effects.
    • These advancements facilitate the use of standard group sequential designs in longitudinal studies.
    • The approach is illustrated with a statin treatment trial for peripheral arterial disease symptoms.